News

  • 10 November 2017

    IONIS LICENSES NOVEL ANTISENSE DRUG FOR THE TREATMENT OF CENTRONUCLEAR MYOPATHY TO DYNACURE

     

     

    Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and Dynacure announced today that Dynacure has licensed IONIS-DNM2-2.5Rx (Dyn101), a Generation 2.5 antisense drug targeting dynamin 2 for the treatment of centronuclear myopathy (CNM), for which Ionis earned a $5 million license fee in the form of Dynacure equity. Dynacure will now assume all development and commercialization responsibilities for the program.

  • 26 September 2017

    Spun out from Conectus Alsace « Proof of Concept » program, Alms Therapeutics close a €15M Series

    Alms Therapeutics, a newly created start-up, based on a Conectus « proof of concept » program representing over €550 000 investment, just closed one of the largest series A round for a newly created start-up in France : €15M invested by Morningside Ventures and Cap Innov’Est.

  • 21 July 2016

    FIRST EUROPEAN WORKSHOP OF MEDTECH ALSACE

    Save the date ! November 15-16th 2016

     

    In the scope of the FrechTech Alsace and in association with the European Materials Research Society, we propose to develop an annual scientific worshop aiming to strenthen cooperation between scientists, companies and investors active in the fields of Nanomedicine, Modelling, Virtual Reality and Robotics applied to Surgery...

     

     

    Download the program and registration form: www.ihu-strasbourg.eu

     

  • 09 June 2016

    Strategic in-licensing and collaboration agreement

    CRISPR Therapeutics and Anagenesis Biotechnologies Announce Strategic In -Licensingand Collaboration Agreement to Develop CRISPR/Cas9-based Cell Therapies for Muscle Diseases   CRISPR Therapeutics Gains Exclusive Worldwide License to Proprietary Paraxial Mesoderm Multipotent Cells (P2MCs) Technology with Initial Research Focused on Duchenne Muscular Dystrophy  
  • 07 June 2016

    Icube Seminar in june

    ICube-MSII seminar
    Biophotonics and The Future of Personal Health Care

     

    Date: 13/06/2016 at 2.00pm Venue: Telecom Physique Strasbourg (A207)

     

  • 03 June 2016

    New technology

    "Death O'Clock" how to know the hour of death

    Investment: 230 600€ over a period of 18 months

    This project is managed by Jonathan Vappou from the team Automatique Vision et Robotique from ICube (CNRS – Unistra).

    Death Oclock consists on a process allowing knowing the exact hour of death when it occurred within the 24 past hours by thermometric method. The thermometric method currently practiced varies a lot according measure conditions, body morphology and conditions in which the death occurred.

  • 27 May 2016

    Partnership with Inria

    Make contractual exchanges with industrialists more fluid and simple: SATT Conectus Alsace and Inria sign a partnership agreement

     

    Inria project teams, in common with the CNRS and the University of Strasbourg*, wish to make their contractual exchanges with industrialists more fluid in order to develop and stimulate partner-oriented research and technologies transfer. Therefore SATT Conectus Alsace and Inria signed an agreement, which aims to simplify and speed up these contracts establishment.

     

  • 15 May 2016

    Best Innovation award

    It is during the 2016 Photonics Europe conference that the IPP team of the ICube laboratory has presented the Photonic Jet station.

    This station is a demonstrator using the principle of photonic burst with a fiber (more information) to laser engraves several materials with a resolution from 0,5 to 10 µm.

    The members, Lecler Sylvain, Zelgowski Julien, Beekenkamp Marc and Mermet Frédéric, who have realized this station, received the prize of the best innovation from “Photonics Innovation Village” at the end of the conference.